Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.43 |
| ▸ | RARA | P10276 | 2/20 | 0.41 |
| ▸ | RARB | P10826 | 2/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13697402 | 0.90 | FFAR4 (0.41) | MCL1FFAR4 | |
| SCHEMBL13697476 | 0.85 | PTGER1 (0.46) | MCL1PTPN11RARARARBRARG | |
| SCHEMBL4154619 | 0.85 | PTGER1 (0.50) | MCL1PTGER1CYP2C9 | |
| SCHEMBL4156359 | 0.83 | PTGER1 (0.52) | PTGER1CYP2C9 | |
| SCHEMBL13697213 | 0.82 | PTGER1 (0.58) | PTGER1CYP2C9 | |
| SCHEMBL4154258 | 0.81 | PTGER1 (0.58) | PTGER1CYP2C9 | |
| SCHEMBL13696734 | 0.80 | ACMSD (0.41) | MCL1DHODHPTGER1CYP2C9 | |
| SCHEMBL4155978 | 0.79 | L3MBTL1 (0.46) | PTGER1CYP2C9 | |
| SCHEMBL4159402 | 0.78 | FFAR4 (0.43) | FFAR4DHODH | |
| SCHEMBL13697448 | 0.76 | PTGER1 (0.44) | MCL1FFAR4PTPN11RARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | MCL1 621/4885FFAR4 2668/4885PTPN11 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.